Market Access
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Novartis Sees Reimbursement Advantage For PCSK9 Launch
Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.
For An Ultra-High-Priced Drug, Alnylam Brings A New Idea
Vertex Versus NHS England: Was The Stand-Off Worth It?
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?
Vertex Finally Inks Orkambi Deal In England
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020
The EMA has declared itself satisfied with ‘refined manufacturing specifications’ for the beta thalassemia treatment
Biopharma Can Live With Boris’s Brexit Deal – But Will It Pass?
Payers Must Brace For Coming Wave Of Cell And Gene Therapies
Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Bayer's Vitrakvi Is EU’s First Tumor-Agnostic Treatment
The German group's cancer drug is the first to be approved for use in Europe for a wide range of tumors. The principal challenge now is to find eligible patients.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.